These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. [Prenatal corticotherapy and acceleration of fetal maturation. II. Results of clinical applications]. Lacaze-Masmonteil T Arch Pediatr; 1996 Nov; 3(11):1119-28. PubMed ID: 8952778 [TBL] [Abstract][Full Text] [Related]
46. Antenatal modes of surfactant administration for RDS prevention: a review. Ostrzenski A; Radolinski B; Ostrzenska KM J Natl Med Assoc; 2006 Mar; 98(3):340-4. PubMed ID: 16573296 [TBL] [Abstract][Full Text] [Related]
47. [Use of glucocorticoids in prevention of the respiratory distress syndrome]. de Oliveira RL; dos Santos MC; Candido DF; el'Debs I Rev Centro Cienc Biomed Univ Fed Uberlandia; 1987 Dec; 3(1):41-7. PubMed ID: 3078405 [TBL] [Abstract][Full Text] [Related]
48. Fetal lung maturation and the antenatal use of glucocorticoids to prevent the respiratory distress syndrome. Shields JR; Resnik R Obstet Gynecol Surv; 1979 May; 34(5):343-63. PubMed ID: 379720 [No Abstract] [Full Text] [Related]
49. The use of exogenous maternal glucocorticoids to prevent neonatal respiratory distress syndrome (RDS)--the state of the facts. Zachman RD Wis Med J; 1976 Sep; 75(9):S91-2. PubMed ID: 969558 [No Abstract] [Full Text] [Related]
50. [Pulmonary surfactant in fetuses and newborn infants. Metabolic maturation of pneumocytes and the role of surfactant proteins]. Groniowski J Patol Pol; 1989; 40(1):1-16. PubMed ID: 2797910 [No Abstract] [Full Text] [Related]
51. Pharyngeal deposition of surfactant in the premature rabbit fetus. Enhörning G; Grossmann G; Robertson B Biol Neonate; 1973; 22(1):126-32. PubMed ID: 4489637 [No Abstract] [Full Text] [Related]
54. Chevalier Jackson Lecture: In quest of the prevention of hyaline membrane disease. Avery ME Ann Otol Rhinol Laryngol; 1977; 86(5 Pt 1):573-6. PubMed ID: 578667 [TBL] [Abstract][Full Text] [Related]
55. Antenatal steroids and the IUGR fetus: are exposure and physiological effects on the lung and cardiovascular system the same as in normally grown fetuses? Morrison JL; Botting KJ; Soo PS; McGillick EV; Hiscock J; Zhang S; McMillen IC; Orgeig S J Pregnancy; 2012; 2012():839656. PubMed ID: 23227338 [TBL] [Abstract][Full Text] [Related]
56. Intrafetal glucose infusion alters glucocorticoid signaling and reduces surfactant protein mRNA expression in the lung of the late-gestation sheep fetus. McGillick EV; Morrison JL; McMillen IC; Orgeig S Am J Physiol Regul Integr Comp Physiol; 2014 Sep; 307(5):R538-45. PubMed ID: 24990855 [TBL] [Abstract][Full Text] [Related]
58. The respiratory distress syndrome and glcocorticoid treatment: the case for enzyme induction. Nathan DM Mt Sinai J Med; 1975; 42(2):150-66. PubMed ID: 1094274 [No Abstract] [Full Text] [Related]
59. [Characteristics of phospholipids of pharyngeal aspirates in newborn infants depending on the use of glucocorticoids in the prenatal period for the prevention of respiratory disorders]. Kuptsov VA Pediatriia; 1984 Mar; (3):32-4. PubMed ID: 6718156 [No Abstract] [Full Text] [Related]
60. Prenatal prevention of respiratory distress syndrome: new pharmacologic approaches. Cosmi EV Early Hum Dev; 1992; 29(1-3):283-6. PubMed ID: 1396253 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]